company background image
IBT

IBEX Technologies TSXV:IBT Stock Report

Last Price

CA$0.57

Market Cap

CA$14.1m

7D

-6.6%

1Y

93.2%

Updated

28 Sep, 2022

Data

Company Financials
IBT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

IBT Stock Overview

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, Germany, and internationally.

IBEX Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for IBEX Technologies
Historical stock prices
Current Share PriceCA$0.57
52 Week HighCA$0.64
52 Week LowCA$0.27
Beta0.25
1 Month Change14.00%
3 Month Change23.91%
1 Year Change93.22%
3 Year Change500.00%
5 Year Change171.43%
Change since IPO-86.59%

Recent News & Updates

Feb 10
We Think Shareholders Will Probably Be Generous With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation

We Think Shareholders Will Probably Be Generous With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation

We have been pretty impressed with the performance at IBEX Technologies Inc. ( CVE:IBT ) recently and CEO Paul Baehr...

Shareholder Returns

IBTCA BiotechsCA Market
7D-6.6%0.4%-2.9%
1Y93.2%-10.3%-5.6%

Return vs Industry: IBT exceeded the Canadian Biotechs industry which returned -14.8% over the past year.

Return vs Market: IBT exceeded the Canadian Market which returned -7.3% over the past year.

Price Volatility

Is IBT's price volatile compared to industry and market?
IBT volatility
IBT Average Weekly Movement14.7%
Biotechs Industry Average Movement11.4%
Market Average Movement9.8%
10% most volatile stocks in CA Market18.2%
10% least volatile stocks in CA Market3.8%

Stable Share Price: IBT is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: IBT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
1986n/aPaul Baehrhttps://www.ibex.ca

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, Germany, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research.

IBEX Technologies Fundamentals Summary

How do IBEX Technologies's earnings and revenue compare to its market cap?
IBT fundamental statistics
Market CapCA$14.15m
Earnings (TTM)CA$1.67m
Revenue (TTM)CA$7.18m

8.5x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IBT income statement (TTM)
RevenueCA$7.18m
Cost of RevenueCA$2.45m
Gross ProfitCA$4.74m
Other ExpensesCA$3.07m
EarningsCA$1.67m

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.067
Gross Margin65.96%
Net Profit Margin23.23%
Debt/Equity Ratio0%

How did IBT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IBT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IBT?

Other financial metrics that can be useful for relative valuation.

IBT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA4.4x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does IBT's PE Ratio compare to its peers?

IBT PE Ratio vs Peers
The above table shows the PE ratio for IBT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average10.6x
MPH Medicure
13xn/aCA$9.8m
MBX Microbix Biosystems
23.8x29.4%CA$72.3m
APC Advanced Proteome Therapeutics
2.6xn/aCA$3.6m
CURE Biocure Technology
3xn/aCA$3.7m
IBT IBEX Technologies
8.5xn/aCA$14.1m

Price-To-Earnings vs Peers: IBT is good value based on its Price-To-Earnings Ratio (8.5x) compared to the peer average (10.6x).


Price to Earnings Ratio vs Industry

How does IBT's PE Ratio compare vs other companies in the North American Biotechs Industry?

Price-To-Earnings vs Industry: IBT is good value based on its Price-To-Earnings Ratio (8.5x) compared to the North American Biotechs industry average (13.5x)


Price to Earnings Ratio vs Fair Ratio

What is IBT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IBT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IBT's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IBT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IBT (CA$0.57) is trading below our estimate of fair value (CA$11.1)

Significantly Below Fair Value: IBT is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is IBEX Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


31.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IBEX Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether IBEX Technologies is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • IBEX Technologies competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has IBEX Technologies performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-6.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IBT has high quality earnings.

Growing Profit Margin: IBT's current net profit margins (23.2%) are higher than last year (19.2%).


Past Earnings Growth Analysis

Earnings Trend: IBT's earnings have declined by 6.8% per year over the past 5 years.

Accelerating Growth: IBT's earnings growth over the past year (61.1%) exceeds its 5-year average (-6.8% per year).

Earnings vs Industry: IBT earnings growth over the past year (61.1%) exceeded the Biotechs industry 34%.


Return on Equity

High ROE: IBT's Return on Equity (17.2%) is considered low.


Discover strong past performing companies

Financial Health

How is IBEX Technologies's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: IBT's short term assets (CA$8.0M) exceed its short term liabilities (CA$1.4M).

Long Term Liabilities: IBT's short term assets (CA$8.0M) exceed its long term liabilities (CA$1.0M).


Debt to Equity History and Analysis

Debt Level: IBT is debt free.

Reducing Debt: IBT has no debt compared to 5 years ago when its debt to equity ratio was 21%.

Debt Coverage: IBT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IBT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is IBEX Technologies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

IBEX Technologies Dividend Yield vs Market
How does IBEX Technologies dividend yield compare to the market?
SegmentDividend Yield
Company (IBEX Technologies)n/a
Market Bottom 25% (CA)2.0%
Market Top 25% (CA)6.0%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (IBEX Technologies)n/a

Notable Dividend: Unable to evaluate IBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IBT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IBT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

9.9yrs

Average board tenure


CEO

Paul Baehr (79 yo)

27.67yrs

Tenure

CA$339,401

Compensation

Mr. Paul Baehr has been the Chairman and Chief Executive Officer of IBEX Technologies, Inc. since October 1995 and serves as its President. He had been Director of Acurx Pharmaceuticals, Inc. Mr. Baehr ser...


CEO Compensation Analysis

Paul Baehr's Compensation vs IBEX Technologies Earnings
How has Paul Baehr's remuneration changed compared to IBEX Technologies's earnings?
DateTotal Comp.SalaryCompany Earnings
Apr 30 2022n/an/a

CA$2m

Jan 31 2022n/an/a

CA$1m

Oct 31 2021n/an/a

CA$1m

Jul 31 2021CA$339kCA$265k

CA$762k

Apr 30 2021n/an/a

CA$1m

Jan 31 2021n/an/a

CA$1m

Oct 31 2020n/an/a

CA$1m

Jul 31 2020CA$348kCA$258k

CA$966k

Apr 30 2020n/an/a

CA$79k

Jan 31 2020n/an/a

-CA$1m

Oct 31 2019n/an/a

-CA$994k

Jul 31 2019CA$246kCA$241k

-CA$1m

Apr 30 2019n/an/a

-CA$704k

Jan 31 2019n/an/a

CA$25k

Oct 31 2018n/an/a

-CA$434k

Jul 31 2018CA$231kCA$211k

-CA$95k

Apr 30 2018n/an/a

CA$2m

Jan 31 2018n/an/a

CA$2m

Oct 31 2017n/an/a

CA$3m

Jul 31 2017CA$248kCA$209k

CA$3m

Apr 30 2017n/an/a

CA$629k

Jan 31 2017n/an/a

CA$165k

Oct 31 2016n/an/a

-CA$61k

Jul 31 2016CA$200kCA$187k

CA$101k

Compensation vs Market: Paul's total compensation ($USD247.92K) is above average for companies of similar size in the Canadian market ($USD177.09K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: IBT's board of directors are considered experienced (9.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of IBT?
Owner TypeNumber of SharesOwnership Percentage
Institutions2,572,35010.4%
Individual Insiders4,052,82716.3%
General Public18,198,06773.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 5 shareholders own 26.69% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.36%
Milfam LLC
2,572,350CA$1.5m0%3.05%
9.9%
Paul Baehr
2,456,477CA$1.4m0%no data
6.07%
Neil Subin
1,506,850CA$858.9k0%no data
0.27%
Robert DeLuccia
68,000CA$38.8k0%no data
0.087%
Danilo Netto
21,500CA$12.3k0%no data

Company Information

IBEX Technologies Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: IBEX Technologies Inc.
  • Ticker: IBT
  • Exchange: TSXV
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$14.149m
  • Shares outstanding: 24.82m
  • Website: https://www.ibex.ca

Location

  • IBEX Technologies Inc.
  • 5485 ParE Street
  • Suite 100
  • Montreal
  • Quebec
  • H4P 1P7
  • Canada


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IBTTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 1996
IBTDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 1996
IBXN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 1996

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/04/30
Annual Earnings2021/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.